About Index Trending news
Analyze
Pricing
Amgen Inc.

Amgen Inc.

Work at Amgen Inc.? Add yourself to this profile

Amgen Inc.

Amgen engages in the development of human therapeutic products in supportive ofcancer care, inflammation, nephrology and bone diseases.
Edit Profile
More info

Elsewhere

Contributors to this profile

Companies in the same industry

BioTime BioTime EternoGen EternoGen Millendo Therapeutics Millendo Therapeutics SutroVax SutroVax miPS Labs miPS Labs HYGIEIA HYGIEIA Lifeshare Technologies Lifeshare Technologies Immunovaccine Inc. Immunovaccine Inc. Multispan Inc Multispan Inc Pure Life Renal Pure Life Renal

Alexa global traffic share

Twitter followers

Terms of Service API Integrations Plans & Pricing
Built with ❤︎ by Datalicious ©2017
A daughter company of TNW.
Index.co is not affiliated with Index Ventures.

Overview

Investments 8

Portfolio

Acquisitions 4

Apps 1
Add info
25 Apr 2017
Science 37
Science 37
$29,000,000
Venture capital (Series C)
Redmile Group, Lux Capital, Glynn Capital Management, +3

GV joins $29 million investment into Science 37 to bring clinical trials to the home

VentureBeat
+1
20 Jul 2016
Akili Interactive
Akili Interactive
$11,900,000
Venture capital (Series B)
Amgen Ventures, Merck Ventures

Amgen and Merck KGaA Invest in Bostons Akili Increasing Funding Round to 42 4 Million

biospace
+1
08 Mar 2016
Tizona Therapeutics
Tizona Therapeutics
$43,000,000
Venture capital (Series B)
Canaan Partners, InterWest Partners, MPM Capital, +4
Added by

Tizona Therapeutics Closes $43M Series B Funding

FinSMEs
07 Jan 2016
Alector
Alector
$29,500,000
Venture capital (Series D)
Polaris Partners, OrbiMed, Topspin Partners, +6
Added by

Alector Raises $29.5M in Series D Financing

FinSMEs
18 Feb 2015
miRagen Therapeutics
miRagen Therapeutics
$8,500,000
Venture capital (Series C)
Atlas Venture, Boulder Ventures, Broadview Ventures, +2
10 Jan 2014
Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc.
$13,500,000
Venture capital (Series B)
DAG Ventures, Kleiner Perkins Caufield & Byers, Celgene, +4
Added by

Atara Biotherapeutics Holds $13.5M Second Close of Series B Financing

FinSMEs
17 Dec 2013
Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc.
$38,500,000
Venture capital (Series B)
DAG Ventures, Kleiner Perkins Caufield & Byers, Celgene, +3
Added by

Atara Biotherapeutics Secures $38.5M in Series B Financing

FinSMEs
14 Jul 2005
Integrated Diagnostics
Integrated Diagnostics
Venture capital (Series A)
ARCH Venture Partners, MPM Capital, OVP Venture Partners, +3
Added by

PE Week Wire - Friday, July 15

PE Hub